Listed

Burning Rock Biotech Ltd

BNRNasdaqCIK 1792267Healthcare

Revenue is not reported in this company’s XBRL financial statements.

Latest quarter: not reported

Last eight quarters

Full statements
Burning Rock Biotech Ltd, key figures for the last eight quarters
Line itemUnitShape over the periods
Revenue$
Gross margin%
Operating margin%
Net margin%
Diluted EPS$ per share
Free cash flow$

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$77.2mGross margin 74.7%
Diluted EPS$0.00, FY2021
Free cash flow−$4.8m, FY2025
Burning Rock Biotech Ltd, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m79.7Revenue, FY2021, twelve months to 2021-12-31$79.7m. XBRL concept us-gaap:Revenues. 20-F filed 2022-04-29, accession 0001193125-22-133522.Report this figure81.7Revenue, FY2022, twelve months to 2022-12-31$81.7m. XBRL concept us-gaap:Revenues. 20-F filed 2023-04-20, accession 0001193125-23-108289.Report this figure75.7Revenue, FY2023, twelve months to 2023-12-31$75.7m. XBRL concept us-gaap:Revenues. 20-F filed 2024-04-29, accession 0001193125-24-119655.Report this figure70.7Revenue, FY2024, twelve months to 2024-12-31$70.7m. XBRL concept us-gaap:Revenues. 20-F filed 2025-04-29, accession 0001193125-25-101753.Report this figure77.2Revenue, FY2025, twelve months to 2025-12-31$77.2m. XBRL concept us-gaap:Revenues. 20-F filed 2026-04-28, accession 0001193125-26-183377.Report this figure
Gross margin%71.7%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $57.1m. XBRL concept us-gaap:GrossProfit. 20-F filed 2022-04-29, accession 0001193125-22-133522.Revenue: $79.7m. XBRL concept us-gaap:Revenues. 20-F filed 2022-04-29, accession 0001193125-22-133522.Report this figure67.5%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $55.1m. XBRL concept us-gaap:GrossProfit. 20-F filed 2023-04-20, accession 0001193125-23-108289.Revenue: $81.7m. XBRL concept us-gaap:Revenues. 20-F filed 2023-04-20, accession 0001193125-23-108289.Report this figure67.6%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $51.2m. XBRL concept us-gaap:GrossProfit. 20-F filed 2024-04-29, accession 0001193125-24-119655.Revenue: $75.7m. XBRL concept us-gaap:Revenues. 20-F filed 2024-04-29, accession 0001193125-24-119655.Report this figure70.3%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $49.6m. XBRL concept us-gaap:GrossProfit. 20-F filed 2025-04-29, accession 0001193125-25-101753.Revenue: $70.7m. XBRL concept us-gaap:Revenues. 20-F filed 2025-04-29, accession 0001193125-25-101753.Report this figure74.7%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $57.6m. XBRL concept us-gaap:GrossProfit. 20-F filed 2026-04-28, accession 0001193125-26-183377.Revenue: $77.2m. XBRL concept us-gaap:Revenues. 20-F filed 2026-04-28, accession 0001193125-26-183377.Report this figure
Operating margin%(156.9%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$125.1m. XBRL concept us-gaap:OperatingIncomeLoss. 20-F filed 2022-04-29, accession 0001193125-22-133522.Revenue: $79.7m. XBRL concept us-gaap:Revenues. 20-F filed 2022-04-29, accession 0001193125-22-133522.Report this figure(174.1%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$142.1m. XBRL concept us-gaap:OperatingIncomeLoss. 20-F filed 2023-04-20, accession 0001193125-23-108289.Revenue: $81.7m. XBRL concept us-gaap:Revenues. 20-F filed 2023-04-20, accession 0001193125-23-108289.Report this figure(124.5%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$94.3m. XBRL concept us-gaap:OperatingIncomeLoss. 20-F filed 2024-04-29, accession 0001193125-24-119655.Revenue: $75.7m. XBRL concept us-gaap:Revenues. 20-F filed 2024-04-29, accession 0001193125-24-119655.Report this figure(69.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$49.0m. XBRL concept us-gaap:OperatingIncomeLoss. 20-F filed 2025-04-29, accession 0001193125-25-101753.Revenue: $70.7m. XBRL concept us-gaap:Revenues. 20-F filed 2025-04-29, accession 0001193125-25-101753.Report this figure(10.2%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$7.8m. XBRL concept us-gaap:OperatingIncomeLoss. 20-F filed 2026-04-28, accession 0001193125-26-183377.Revenue: $77.2m. XBRL concept us-gaap:Revenues. 20-F filed 2026-04-28, accession 0001193125-26-183377.Report this figure
Net margin%(156.9%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$125.0m. XBRL concept us-gaap:NetIncomeLoss. 20-F filed 2022-04-29, accession 0001193125-22-133522.Revenue: $79.7m. XBRL concept us-gaap:Revenues. 20-F filed 2022-04-29, accession 0001193125-22-133522.Report this figure(172.4%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$140.8m. XBRL concept us-gaap:NetIncomeLoss. 20-F filed 2023-04-20, accession 0001193125-23-108289.Revenue: $81.7m. XBRL concept us-gaap:Revenues. 20-F filed 2023-04-20, accession 0001193125-23-108289.Report this figure(121.6%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$92.1m. XBRL concept us-gaap:NetIncomeLoss. 20-F filed 2024-04-29, accession 0001193125-24-119655.Revenue: $75.7m. XBRL concept us-gaap:Revenues. 20-F filed 2024-04-29, accession 0001193125-24-119655.Report this figure(67.2%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$47.5m. XBRL concept us-gaap:NetIncomeLoss. 20-F filed 2025-04-29, accession 0001193125-25-101753.Revenue: $70.7m. XBRL concept us-gaap:Revenues. 20-F filed 2025-04-29, accession 0001193125-25-101753.Report this figure(10.3%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$7.9m. XBRL concept us-gaap:NetIncomeLoss. 20-F filed 2026-04-28, accession 0001193125-26-183377.Revenue: $77.2m. XBRL concept us-gaap:Revenues. 20-F filed 2026-04-28, accession 0001193125-26-183377.Report this figure
Diluted EPS$ per share0.00Diluted EPS, FY2021, twelve months to 2021-12-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 20-F filed 2022-04-29, accession 0001193125-22-133522.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(107)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$75.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2022-04-29, accession 0001193125-22-133522.Capital expenditure: $32.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2022-04-29, accession 0001193125-22-133522.Report this figure(75.2)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$66.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2023-04-20, accession 0001193125-23-108289.Capital expenditure: $9.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2023-04-20, accession 0001193125-23-108289.Report this figure(37.2)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$36.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2024-04-29, accession 0001193125-24-119655.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2024-04-29, accession 0001193125-24-119655.Report this figure(13.4)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$12.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2025-04-29, accession 0001193125-25-101753.Capital expenditure: $742.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2025-04-29, accession 0001193125-25-101753.Report this figure(4.8)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$4.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2026-04-28, accession 0001193125-26-183377.Capital expenditure: $751.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2026-04-28, accession 0001193125-26-183377.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Burning Rock Biotech Ltd
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Kynam Capital Management, LP2026-06-30$10.5m1,238,563Added+11,008
CRCM LP2026-06-30$1.8m211,997Reduced−70,100
CRCM LP2026-06-30$1.8m211,997Reduced−70,100
RENAISSANCE TECHNOLOGIES LLC2026-06-30$442.3k52,838Added+17,431
MORGAN STANLEY2026-06-30$364.9k43,594Added+28,322
Amova Asset Management Americas, Inc.2026-06-30$257.7k29,724Reduced−413
Sumitomo Mitsui Trust Group, Inc.2026-06-30$248.8k29,724Reduced−413
BANK OF AMERICA CORP /DE/2026-06-30$244.1k29,164Unchanged
CITADEL ADVISORS LLC2026-06-30$236.6k27,288Added+9,619
HSG Holding Ltd2026-06-30$177.5k21,212Unchanged

Recent filings

All 166 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Burning Rock Biotech Ltd, recent filings
FiledFormWhat it isAccession number
2026-09-1007:01 ET6-KReport of a foreign private issuerPeriod 2026-09-100001193125-26-387190
2026-06-0906:04 ET6-KReport of a foreign private issuerPeriod 2026-06-090001193125-26-262871
2026-04-2806:08 ET20-FAnnual report of a foreign private issuerPeriod 2025-12-310001193125-26-183377
2026-03-1320:58 ET6-KReport of a foreign private issuerPeriod 2026-03-120001193125-26-104743
2025-12-2306:11 ET6-KReport of a foreign private issuerPeriod 2025-12-230001193125-25-329450
2025-12-0109:56 ET6-KReport of a foreign private issuerPeriod 2025-12-010001193125-25-303306
2025-11-2006:05 ET6-KReport of a foreign private issuerPeriod 2025-11-200001193125-25-288773
2025-09-0806:06 ET6-KReport of a foreign private issuerPeriod 2025-09-080001193125-25-197601
2025-06-0606:07 ET6-KReport of a foreign private issuerPeriod 2025-06-060001193125-25-136266
2025-04-2906:31 ET20-FAnnual report of a foreign private issuerPeriod 2024-12-310001193125-25-101753

Latest annual report

Form 20-F for the fiscal year ended Dec 31, 2025Filed Apr 28, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1792267
Tickers
BNR
Exchange
Nasdaq
SIC code
8071 Services-Medical Laboratories
Sector
Healthcare
Fiscal year ends
not reported
Incorporated in
not reported
Filer category
Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.